LIMES Schlosskliniken (LIK) H1 2026 earnings summary

Executive summary

• Total revenues rose 28.3% year-over-year to €30.7 million for the first half of 2026, driven by new clinic openings and strong performance at the Zurich location.

• EBITDA increased 12.3% to €7.0 million, while EBIT grew 2.7% to €5.0 million, reflecting higher operating costs from expansion.

• Net income attributable to shareholders declined 5.7% to €3.1 million, with EPS down 7.2% to €10.49.

• Patient days increased 17.5% year-over-year, with new clinics Abtsee and Bergisches Land contributing €7.4 million in revenue.

• European expansion continues, with acquisition plans for a new clinic in Tuscany and stabilization expected at new German clinics.

Financial highlights

• Gross earnings (EBITDA) reached €7.0 million, up 12.3% year-over-year.

• Operating result (EBIT) was €5.0 million, up 2.7% year-over-year.

• Earnings before taxes (EBT) slightly decreased by 1.1% to €4.86 million.

• Cash flow from operating activities increased 72.8% to €5.48 million.

• Cash and cash equivalents at period end were €8.2 million, down 25.8% year-over-year.

Outlook and guidance

• Second half performance will be influenced by the continued ramp-up of new clinics.

• Weaker performance expected at Mecklenburgische Schweiz Clinic due to a swimming pool malfunction, with repairs to be completed by year-end.

• Anticipated opening of the Tuscany clinic in summer 2027, aligning with stabilization of new German clinics.